Zenas BioPharma ZBIO
Zenas BioPharma Q2 FY25: revenue $0; diluted EPS −$1.25
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001558370-25-011147
- Document
- 10-Q
- Exhibit 10.1
- Material contract
- Exhibit 10.2
- Material contract
Key figures from this report
These are the numbers Zenas BioPharma reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$0No year-earlier figure tagged10-Q income statement, on EDGAR
- Net income−$52.2MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS−$1.25No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$44.0MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$41.7MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Atea Pharmaceuticals AVIR public float $263M, Jun 30, 2025
- Verastem VSTM public float $254M, Jun 30, 2025
- Corvus Pharmaceuticals CRVS public float $252M, Jun 30, 2025
- DBV Technologies DBVT public float $251M, Jun 30, 2025
- Vanda Pharmaceuticals VNDA public float $269M, Jun 30, 2025